US EditionPublished • loading... • Updated
Eye-tracking measures to aid evaluation in Parkinson's clinical trial
Summary by Parkinson's News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Eye-tracking measures to aid evaluation in Parkinson's clinical trial
A clinical trial testing Teitur Trophics‘ TT-P34 in Parkinson’s disease will use Neuralight‘s brain function biomarker based on eye movement to assess neural circuitry, the companies announced. Neuralight’s platform provides precise measures of brain function derived from eye movements, based on well-established links between specific eye movement patterns and underlying neural circuitry. Teitur is developing TT-P34 for several neurological cond…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
